These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
348 related articles for article (PubMed ID: 24565533)
1. Comparison of prognostic impact of absolute lymphocyte count, absolute monocyte count, absolute lymphocyte count/absolute monocyte count prognostic score and ratio in patients with diffuse large B cell lymphoma. Markovic O; Popovic L; Marisavljevic D; Jovanovic D; Filipovic B; Stanisavljevic D; Matovina-Brko G; Hajder J; Matkovic T; Živkovic R; Stanisavljevic N; Todorović M; Petrovic D; Mihaljevic B Eur J Intern Med; 2014 Mar; 25(3):296-302. PubMed ID: 24565533 [TBL] [Abstract][Full Text] [Related]
2. The prognostic impact of absolute lymphocyte and monocyte counts at diagnosis of diffuse large B-cell lymphoma in the rituximab era. Aoki K; Tabata S; Yonetani N; Matsushita A; Ishikawa T Acta Haematol; 2013; 130(4):242-6. PubMed ID: 23860478 [TBL] [Abstract][Full Text] [Related]
3. Peripheral blood lymphocyte/monocyte ratio predicts outcome for patients with diffuse large B cell lymphoma after standard first-line regimens. Li YL; Pan YY; Jiao Y; Ning J; Fan YG; Zhai ZM Ann Hematol; 2014 Apr; 93(4):617-26. PubMed ID: 24141331 [TBL] [Abstract][Full Text] [Related]
4. The lower peripheral blood lymphocyte/monocyte ratio assessed during routine follow-up after standard first-line chemotherapy is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma. Yan-Li L; Kang-Sheng G; Yue-Yin P; Yang J; Zhi-Min Z Leuk Res; 2014 Mar; 38(3):323-8. PubMed ID: 24439567 [TBL] [Abstract][Full Text] [Related]
5. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab. Oki Y; Yamamoto K; Kato H; Kuwatsuka Y; Taji H; Kagami Y; Morishima Y Eur J Haematol; 2008 Dec; 81(6):448-53. PubMed ID: 18691256 [TBL] [Abstract][Full Text] [Related]
6. Neutrophil/Lymphocyte Ratio, Lymphocyte/Monocyte Ratio, and Absolute Lymphocyte Count/Absolute Monocyte Count Prognostic Score in Diffuse Large B-Cell Lymphoma: Useful Prognostic Tools in the Rituximab Era. Ho CL; Lu CS; Chen JH; Chen YG; Huang TC; Wu YY Medicine (Baltimore); 2015 Jun; 94(24):e993. PubMed ID: 26091479 [TBL] [Abstract][Full Text] [Related]
7. Absolute monocyte/lymphocyte count prognostic score is independent of immunohistochemically determined cell of origin in predicting survival in diffuse large B-cell lymphoma. Porrata LF; Ristow K; Habermann TM; Ozsan N; Dogan A; Macon W; Colgan JP; Witzig TE; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Nowakowski GS; Thompson C; Markovic SN Leuk Lymphoma; 2012 Nov; 53(11):2159-65. PubMed ID: 22551474 [TBL] [Abstract][Full Text] [Related]
8. Peripheral blood absolute lymphocyte/monocyte ratio as a useful prognostic factor in diffuse large B-cell lymphoma in the rituximab era. Watanabe R; Tomita N; Itabashi M; Ishibashi D; Yamamoto E; Koyama S; Miyashita K; Takahashi H; Nakajima Y; Hattori Y; Motohashi K; Takasaki H; Ohshima R; Hashimoto C; Yamazaki E; Fujimaki K; Sakai R; Fujisawa S; Motomura S; Ishigatsubo Y Eur J Haematol; 2014 Mar; 92(3):204-10. PubMed ID: 24283206 [TBL] [Abstract][Full Text] [Related]
9. Relationship between the absolute lymphocyte count/absolute monocyte count ratio, soluble interleukin 2 receptor level, serum programmed cell death 1 level, and the prognosis of patients with diffuse large B-cell lymphoma. Li C; Li W; Xu G; You M; Wu W; Kuang L Ann Palliat Med; 2021 Oct; 10(10):10938-10945. PubMed ID: 34763456 [TBL] [Abstract][Full Text] [Related]
10. Low lymphocyte-to-monocyte ratio predicts unfavorable prognosis in non-germinal center type diffuse large B-cell lymphoma. Wei X; Huang F; Wei Y; Jing H; Xie M; Hao X; Feng R Leuk Res; 2014 Jun; 38(6):694-8. PubMed ID: 24713260 [TBL] [Abstract][Full Text] [Related]
11. Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma. Porrata LF; Ristow KM; Habermann TM; Witzig TE; Colgan JP; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Nowakowski G; Thompson CA; Markovic SN Leuk Lymphoma; 2014 Dec; 55(12):2728-38. PubMed ID: 24547705 [TBL] [Abstract][Full Text] [Related]
12. The prognostic utility and the association of serum light chains (free and total) and absolute lymphocyte count in patients with newly diagnosed diffuse large B-cell lymphoma. Han X; Wang J; Zhang N; Yao J; Feng Y; Li D; Liu P; Yang J; Zhou S; Qin Y; Yang S; Gui L; He X; Shi Y Leuk Res; 2014 Nov; 38(11):1291-8. PubMed ID: 25287608 [TBL] [Abstract][Full Text] [Related]
13. The Role of Lymphocyte to Monocyte Ratio, Microvessel Density and HiGH CD44 Tumor Cell Expression in Non Hodgkin Lymphomas. Jelicic J; Balint MT; Jovanovic MP; Boricic N; Micev M; Stojsic J; Antic D; Andjelic B; Bila J; Balint B; Pavlovic S; Mihaljevic B Pathol Oncol Res; 2016 Jul; 22(3):567-77. PubMed ID: 26750138 [TBL] [Abstract][Full Text] [Related]
14. Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell lymphoma. Porrata LF; Ristow K; Habermann TM; Witzig TE; Inwards DJ; Markovic SN Am J Hematol; 2009 Feb; 84(2):93-7. PubMed ID: 19123458 [TBL] [Abstract][Full Text] [Related]
15. Peripheral blood lymphocyte/monocyte ratio at the time of first relapse predicts outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Li YL; Gu KS; Pan YY; Jiao Y; Zhai ZM BMC Cancer; 2014 May; 14():341. PubMed ID: 24884604 [TBL] [Abstract][Full Text] [Related]
16. Absolute monocyte and lymphocyte count prognostic score for patients with gastric cancer. Eo WK; Jeong DW; Chang HJ; Won KY; Choi SI; Kim SH; Chun SW; Oh YL; Lee TH; Kim YO; Kim KH; Ji YI; Kim A; Kim HY World J Gastroenterol; 2015 Mar; 21(9):2668-76. PubMed ID: 25759535 [TBL] [Abstract][Full Text] [Related]
17. Prognostic Implication of the Absolute Lymphocyte to Absolute Monocyte Count Ratio in Patients With Classical Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine or Equivalent Regimens. Vassilakopoulos TP; Dimopoulou MN; Angelopoulou MK; Petevi K; Pangalis GA; Moschogiannis M; Dimou M; Boutsikas G; Kanellopoulos A; Gainaru G; Plata E; Flevari P; Koutsi K; Papageorgiou L; Telonis V; Tsaftaridis P; Sachanas S; Yiakoumis X; Tsirkinidis P; Viniou NA; Siakantaris MP; Variami E; Kyrtsonis MC; Meletis J; Panayiotidis P; Konstantopoulos K Oncologist; 2016 Mar; 21(3):343-53. PubMed ID: 26921291 [TBL] [Abstract][Full Text] [Related]
19. Prognostic value of lymphocyte/monocyte ratio in advanced Hodgkin lymphoma: correlation with International Prognostic Score and tumor associated macrophages. Jakovic LR; Mihaljevic BS; Andjelic BM; Bogdanovic AD; Perunicic Jovanovic MD; Babic DD; Bumbasirevic VZ Leuk Lymphoma; 2016 Aug; 57(8):1839-47. PubMed ID: 26727349 [TBL] [Abstract][Full Text] [Related]
20. Comparison of prognostic models for patients with diffuse large B-cell lymphoma in the rituximab era. Huang YC; Liu CY; Lu HJ; Liu HT; Hung MH; Hong YC; Hsiao LT; Gau JP; Liu JH; Hsu HC; Chiou TJ; Chen PM; Tzeng CH; Yu YB Ann Hematol; 2013 Nov; 92(11):1513-20. PubMed ID: 23775580 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]